
May 28, 2025
Study Shows Proliferation Of GLP-1s A new study finds that the number of people prescribed GLP-1 drugs for weight management has skyrocketed over the past five years. FAIR Health’s study finds that just over 2% of adults in the U.S. took a GLP-1 to treat obesity or being overweight in 2024, up from just 0.3% in 2019. For those not diabetic, the percent of such adults increased from 0.03% in 2019 to 0.67% in 2019, or 1,960.9%. While big national providers have sought to expand GLP-1 coverage while de-risking impacts, other plans are discontinuing coverage due to surging costs. A number of Blues are discontinuing obesity-only GLP-1 coverage. In other news, compounders continue filling compounded GLP-1 drugs by arguing individual formulations are allowable. Additional article: https://www.modernhealthcare.com/insurance/bcbs-plans-michigan-massachusetts-glp1-coverage and https://www.healthcaredive.com/news/glp1-obesity-weight-loss-adoption-fair-health/748963/ and https://insidehealthpolicy.com/inside-drug-pricing-daily-news/telehealth-companies-use-loophole-continue-glp-1-sales (Some articles may require a subscription.) #weightlossdrugs #glp1s #healthplans #pbms #drugpricing #branddrugmakers https://www.fiercehealthcare.com/payers/fair-health-heres-how-much-glp-1-prescriptions-obesity-overweight-have-grown-2019 MA Industry Divided On Risk Adjustment Audits
